Abstract
As no specific genetic lesions have yet been identified, the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms is based on a simultaneous evaluation of the clinical, morphological and molecular features defined by the updated WHO classification, which allow most cases of full-blown disease to be classified. Nevertheless, about 10-15% of the patients have unclassifiable myeloproliferative neoplasms, most of whom are in the prodromal (early) phase of disease and identified by the presence of the JAK2 mutation, but lack the complete phenotype required by the WHO classification. The detection of these prodromal phases is extremely important in order to prevent dramatic thrombo-hemorrhagic complications and improve prognosis.
| Original language | English |
|---|---|
| Pages (from-to) | 255-264 |
| Number of pages | 10 |
| Journal | Expert Review of Hematology |
| Volume | 7 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Bone marrow
- essential thrombocythemia
- megakaryocyte
- myelofibrosis
- myeloproliferative neoplasms
- polycythemia vera
- primary myelofibrosis
ASJC Scopus subject areas
- Hematology
Cite this
Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. / Gianelli, Umberto; Iurlo, Alessandra; Cattaneo, Daniele; Lambertenghi-Deliliers, Giorgio.
In: Expert Review of Hematology, Vol. 7, No. 2, 2014, p. 255-264.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms
AU - Gianelli, Umberto
AU - Iurlo, Alessandra
AU - Cattaneo, Daniele
AU - Lambertenghi-Deliliers, Giorgio
PY - 2014
Y1 - 2014
N2 - As no specific genetic lesions have yet been identified, the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms is based on a simultaneous evaluation of the clinical, morphological and molecular features defined by the updated WHO classification, which allow most cases of full-blown disease to be classified. Nevertheless, about 10-15% of the patients have unclassifiable myeloproliferative neoplasms, most of whom are in the prodromal (early) phase of disease and identified by the presence of the JAK2 mutation, but lack the complete phenotype required by the WHO classification. The detection of these prodromal phases is extremely important in order to prevent dramatic thrombo-hemorrhagic complications and improve prognosis.
AB - As no specific genetic lesions have yet been identified, the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms is based on a simultaneous evaluation of the clinical, morphological and molecular features defined by the updated WHO classification, which allow most cases of full-blown disease to be classified. Nevertheless, about 10-15% of the patients have unclassifiable myeloproliferative neoplasms, most of whom are in the prodromal (early) phase of disease and identified by the presence of the JAK2 mutation, but lack the complete phenotype required by the WHO classification. The detection of these prodromal phases is extremely important in order to prevent dramatic thrombo-hemorrhagic complications and improve prognosis.
KW - Bone marrow
KW - essential thrombocythemia
KW - megakaryocyte
KW - myelofibrosis
KW - myeloproliferative neoplasms
KW - polycythemia vera
KW - primary myelofibrosis
UR - http://www.scopus.com/inward/record.url?scp=84896368819&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896368819&partnerID=8YFLogxK
U2 - 10.1586/17474086.2014.876898
DO - 10.1586/17474086.2014.876898
M3 - Article
C2 - 24524231
AN - SCOPUS:84896368819
VL - 7
SP - 255
EP - 264
JO - Expert Review of Hematology
JF - Expert Review of Hematology
SN - 1747-4086
IS - 2
ER -